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Lack of correlation between urea kinetic indices and clinical
outcomes in CAPD patients
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Lack of correlation between urea kinetic indices and clinical outcomes
in CAPD patients. We examined the predictive value of urea kinetics for
patient outcomes in CAPD by measuring dialysis index (DI; a means of
quantifying CAPD dose using urea kinetics), KT/V and normalized
protein catabolic rate (PCRN) on 222 occasions in 76 new patients at the
time of starting CAPD and at subsequent six month intervals. We
investigated how these indices altered with time and in relation to each
other, and how they correlated with a wide range of subsequent patient
outcomes. Dl, KT/V and PCRN all tended to decrease with time on
CAPD (P < 0.0004, <0.0001 and 0.0005, respectively). DI and KT/V
were highly correlated with each other (r = 0.89, P < 0,0001) and both
correlated with PCRN (r = 0.57, P < 0.0001 and r = 0.60, P < 0.0001,
respectively). DI and KT/V both correlated inversely with subsequent
values for serum creatinine (P < 0.0001), urea (P < 0.0002), potassium(P < 0.02) and phosphate (P < 0.002), and directly with bicarbonate (P
< 0.0001). PCRN correlated inversely with serum creatinine (P <
0.0002) and directly with urea (P < 0.0001) and with the number of
blood transfusions received (P < 0.03). None of the indices correlated
with levels of hemoglobin, PTH, alkaline phosphatase or albumin, or
with nerve conduction velocity or any other subsequent clinical out-
comes including death, technique failure, hospital days, peritonitis rate
and subjective indices of fatigue, pruritus and insomnia. We conclude
that the urea kinetic model is predictive of some biochemical outcomes
but not of clinical outcomes in CAPD patients.
The National Cooperative Dialysis Study, published in 1983,
showed that the urea kinetic model is predictive of clinical
outcomes in hemodialysis patients [1], and that the KT/V index
and the normalized protein catabolic rate (PCRN) can be
monitored and used to prescribe hemodialysis in a scientific
manner [2].
No such study had been done for continuous ambulatory
peritoneal dialysis (CAPD) and it is unclear if the urea kinetic
model also applies to this dialytic mode. It is well recognized
that, by the standards of urea kinetics, many CAPD patients are
very underdialyzed [3] but, in spite of this, most studies show
no significant difference in morbidity or mortality between
CAPD and hemodialysis patients [4—6j. This suggests that other
factors may be important in determining adequacy of dialysis in
CAPD and, clearly, this has important implications for the
manner in which CAPD is prescribed.
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We prospectively investigated the predictive value of urea
kinetics in a cohort of 76 new CAPD patients by measuring
dialysis index (DI), KT/V and PCRN at the time of initial
training and at subsequent six month intervals and by compar-
ing the values obtained with subsequent patient outcomes.
DI is a concept originated by Teehan et alto allow simple
application of urea kinetics of CAPD, and is a ratio between the
actual daily dialysate drainage volume and that volume which
would be required to keep the BUN at 25 mmol/liter if the
protein intake was 1.2 mg/kg/day [7]. These target values for
BUN and protein intake were chosen by Teehan et al as
appropriate consensus figures on the basis of a review of the
literature, but even this relatively high protein intake may not
be adequate to achieve nitrogen balance in some CAPD patients
with high dialysate protein losses [7]. DI has the same three
determinants as KT/V: body weight, residual renal function,
and daily dialysate drainage volume. We chose to measure both
DI and KT/V because, although the former was specifically
designed for CAPD, the latter remains better known and
permits easier comparison with hemodialysis.
Methods
Patients
Seventy-six new adult, end-stage renal failure patients, com-
mencing CAPD between July 1984 and December 1986, were
studied at the time of initial training and, where possible, at
subsequent six month intervals until July 1989. There were 52
males and 24 females; the mean age at onset was 56.9 years
(range 18 to 81) and 22 (29%) had diabetic nephropathy as their
cause of renal failure.
Study protocol
Each study involved a 24 hour admission for measurement of
DI, KT/V and PCRN.
DI was calculated by measuring the 24-hour dialysate drain-
age volume and the residual renal urea clearance, and by
estimating clinically the ideal body weight (IBW) for each
patient. DI is the ratio of the actual daily dialysate drainage
volume (DDDV) to that volume which would be required to
maintain that patient's BUN at 25 mmol/liter if protein intake
were 1.2 g!kg/day. The formula used to calculate DI takes into
account not only dialysate removal of urea but also the rela-
tively high nonurea nitrogen losses typical of CAPD (Table 1)
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Table 1. Calculation of dialysis index, KT/V and normalized protein
catabolic rate
DI - Actual DDDV—
Required DDDV
Required DDDV = (0.23 x IBW) — (2.6 + 1.44 KrU)a (that is, for
BUN 25 mmol/liter and protein intake 1.2 g/kglday)
7 fActual DDDV + 1.44 KrUKT/V = - _______________
3 Total body water
PCR
PCRN (g/kg/day) =
PCR = sum of
(1) Daily dialysate urea losses'
(2) Daily dialysate protein losses(3) Daily urine urea losses'
(4) Daily urine protein losses
(5) Estimated daily dialysate amino acid lossesc (0.5 g N)
(6) Estimated miscellaneous nonurea nitrogen lossesc
[(0.31 x IBW) g N]
a KrU = residual renal urea clearance (mI/mm)
b Estimated as IBW x 0.6 for males and as IBW >< 0.55 for females
C Expressed in grams of nitrogen per day and divided by 0.16 to
convert to grams of protein per day.
[7]. IBW was taken to be the lowest weight at which the patient
could be maintained without signs or symptoms indicative of
volume depletion.
KT/V was measured for the 24 hour period by substituting the
sum of the actual DDDV and the daily residual renal urea
clearance for KT, and by using 60% and 55% of IBW as
estimates for V in males and females, respectively. The result-
ing daily KTIV values were multiplied by 7 and divided by 3 to
allow easy direct comparison with KT/V values from conven-
tional three-times weekly hemodialysis regimes. While such an
extrapolation is artificial, it is our experience that it greatly
facilitates comprehension of KT/V in CAPD and, indeed, has
been used in this form in other studies [3].
During each study the patient followed a set protocol of four
two-liter exchanges comprising three four-hour dwells (Dianeal
1.5%, 2.5% and 4.25%, respectively) and one overnight 12-hour
dwell (Dianeal 1.5%). In cases where the patients' regular
CAPD regime was other than two-liters four times daily, that
patient's actual DDDV was measured and used in the formulas
instead.
PCRN was calculated by measuring 24 hour urine and dialy-
sate collections for both urea and protein content. An estimate
was added for daily dialysate amino acid losses and for miscel-
laneous nonurea nitrogen losses as described by Teehan et a!
(Table 1)17]. This gave a value for protein catabolic rate which
was then normalized for IBW to give PCRN (g/kglday).
During the follow-up period all patients were prescribed
protein intakes of 1.2 to 1.4 g/kg/day, although subsequent
monitoring showed that this was rarely achieved.
The standard CAPD regime prescribed was two liters, four
times daily, although in 42 of the patients, this was subse-
quently altered on clinical grounds at the discretion of the
patients' physicians. Indications for these alterations were: (1)
biochemical results or signs and symptoms suggesting inade-
quate control of uremia (15 patients) as a result of which daily
dialysate volume was increased, typically to 2.5 liters, four
times daily or 3-liters, three times daily as the physician felt
appropriate; (2) reluctance or inability of the patient to do four
exchanges daily (24 patients), as a result of which the regime
was altered, typically to 2.5 or 3 liters, three times daily
depending on biochemical results and tolerance of higher dwell
volumes; (3) complications related to high intra-abdominal
pressure such as back pain or hernias (3 patients), as a result of
which dwell volumes were decreased to 1.5 liters, four or five
times daily as was judged appropriate. At all times the physi-
cians made these decisions without knowing DI, KT/V or
PRCN.
Outcomes
During the six month period subsequent to each study
patients had monthly measurements of a range of biochemical
indices including serum creatinine, urea, potassium, bicarbon-
ate, phosphate, alkaline phosphatase, hemoglobin and albumin.
Values were averaged for each six month period. Parathyroid
hormone levels were measured on a six month basis (intact
molecule assay).
Clinical outcomes monitored every six months included
death, technique failure, hospitalization days, peritonitis rate
and units of red cells transfused. In addition patients marked on
a zero-to-three scale monthly estimates of fatigue, pruritus and
insomnia with 0,1,2 and 3 meaning absent, mild, moderate and
severe symptomatology, respectively. Values were averaged
over six months to give fatigue, pruritus and insomnia indices.
Nerve conduction velocity (rn/see) was measured in the
lateral peroneal nerve every six months.
When patients did not complete a six month follow-up period
due to death or technique drop out, outcomes were corrected
for the shorter period by averaging the recorded monthly values
over the shorter time. In the case of peritonitis, hospitalization
and transfusions the analysis was also done with uncorrected
values as it was thought that, where follow-up was two months
or less, extrapolation to give a six month rate might be mislead-
ing, that is, one peritonitis episode in one month leading to drop
out might not be best represented as six episodes in six months.
Drop outs due to transplantation and recovery of renal function
were not recorded as technique failures but transfers to other
peritoneal dialysis modalities, such as cycler dialysis, as well as to
hemodialysis were recorded.
Correlations were sought between DI, KT/V and PCRN at
each study and biochemical and clinical outcomes over the
subsequent six months. Outcomes occurring more than six
months after the patient's last study were not included in the
analysis, with the exception of deaths and technique failures
which were included if they occurred up to 12 months after the
last study.
In addition, an alternative analysis was done by taking the
data from only the 51 patients who had more than one study
performed. In each of these patients an average DI, KT/V and
PCRN was calculated from all studies done up to 24 months
after starting CAPD, and correlations were sought with out-
comes averaged over the follow up period up to 30 months after
starting CAPD. The rationale behind this alternative patient
based analysis, (that is, one data point per patient) was the
concern that the results from the study based analysis (that is,
one data point per six month study) might have been biased by
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or more
Number of studies per patient
Death 13a
Hemodialysis 7a
Other peritoneal dialysis 7
Total technique failures 25
Transplantation 21
Recovered renal function 1
Transferred elsewhere 4
Refused follow-up studies 7
Completed follow-up 18
a Two patients are counted twice as death occurred after transfer to
hemodialysis (I patient) or to other peritoneal dialysis (I patient) but
within designated follow-up period.
the fact that patients who continued longer on CAPD contrib-
uted more data points to the database.
Statistics
Data is expressed as mean SD where relevant, unless
otherwise stated. Correlations were measured using Pearson's
correlation coefficient and differences between groups were
measured using paired or unpaired t-tests as appropriate. Sig-
nificance was assumed at a P value less than 0.05.
Results
Follow-up
The 76 patients had 222 studies performed at intervals of six
or more months (Fig. 1). This represents a mean of 2.9 studies
per patient over a follow-up period averaging 19.9 months
(range 1 to 57). During the follow-up period there was a high
drop out rate due to a range of causes (Table 2). There were a
total of 93 peritonitis episodes (0.84 per patient year), 156
hospital days (14.1 per patient year) and 199 units of red cells
transfused (1.8 per patient year).
DI, KTIV and PCRN. The mean DI over 222 studies was 0.97
0.56 with a range from 0.42 to 4,0. In 60% of studies DI was
less than 0.9 and in 30% it was less than 0.7. In contrast, in five
studies DI exceeded 3.7. Mean KT/V was 0.68 0.21 (range
0.32 to 1.77). As expected, DI and KT/V were highly correlated
with each other (r = 0.89, P < 0.0001).
Both DI and KT/V had a strong tendency to decrease with
time (P < 0.0004 and <0.0001, respectively; Figs. 2 and 3).
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Fig. 3. Change in KTIV with time on CAPD. Figures in brackets show
number of patients at each six month interval. Points and bars represent
mean values and standard deviations.
The major reason for the decline in DI and KT/V was the
decrease with time in residual renal urea clearance (P < 0.0001)
which averaged 1.56 mIs per minute at the time of starting
CAPD and which was negligible by 30 months (Fig. 4). There
was also a tendency for daily net ultrafiltration volumes on the
standard two-liters four times daily regime to decrease with
time from a mean 1.40 0.77 liters at the time of starting
CAPD, to 1.21 0.54 liters at 12 months and 0.84 0.73 liters
at 30 months (differences significant at P < 0.05 and < 0.02,
respectively). IBW tended to increase with time from a mean of
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Fig. 1. Frequency distribution of numbers of studies per patient.
Table 2. Eventual outcome in 76 patients
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Fig. 2. Changes in DI with time on CAPD. Figures in brackets show
number of patients at each six month interval. Points represent mean
values. Standard deviations are not shown as DI is not normally
distributed.
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Fig. 4. Change in residual renalfunction with time on CAPD. Figures
in brackets show number of patients at each six month interval. Points
and bars represent mean values and standard errors of the mean.
63.5 13.5 kg at time zero to 68.3 16.3 kg at 12 months, and
66.2 10.9 kg at 24 months (P < 0.001 and < 0.05, respec-
tively, using paired t-test).
The mean PCRN from 220 studies was 0.97 0.22 with a
range from 0.50 to 1.73 g/kglday. PCRN also tended to decrease
with time (P < 0.0005; Fig. 5). There was a strong correlation
between PCRN and both DI (r = 0.57, r2 = 0.32, P < 0.0001)
and KT/V (r = 0.60, r2 = 0.36, P < 0.0001; Figs. 6 and 7).
Daily dialysate protein losses averaged 8.33 3.15 grams
(range 1.0 to 21.2) and did not alter significantly with time.
Biochemical outcomes
DI correlated inversely with serum levels of creatinine (r =
0.36, P < 0.0001), urea (r = 0.25, P < 0.005), potassium (r =
0.16, P < 0.05) and phosphate (r = 0.21, P < 0.01) and directly
with bicarbonate (r = 0.29, P < 0.0001). It did not correlate with
hemoglobin, albumin, alkaline phosphatase or parathyroid hor-
mone levels. Correlations for KT/V were similar to those for
DI.
PCRN correlated directly with serum levels of urea (r = 0.26,
P < 0.001) and inversely with creatinine (r = 0.31, P < 0.0001),
but not with any other biochemical parameters.
Clinical outcomes
DI and KT/V did not correlate with any clinical outcomes nor
did PCRN except for a weak positive correlation with units of
red cells transfused (r = 0.16, P < 0.05).
In particular, mean values for DI and PCRN in 13 studies
after which death occurred were 1.01 0.92 and 1.02 0.27,
respectively, as compared with 0.97 0.53 and 0,97 0.22,
respectively, in 209 studies after which death did not occur.
Similarly, values for DI and PCRN in 25 studies after which
technique failure occurred were 0.94 0.69 and 0.95 0.24
compared to 0.98 0.54 and 0.97 0.22, respectively, in 197
studies after which technique failures did not occur (all differ-
ences not significant).
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Fig. 5. Change in PCRN with time on CAPD. Figures in brackets show
number of patients at each six month interval. Mean values and
standard deviations are represented by points and bars.
To maximise the chance of detecting a predictive value for DI
and PCRN with regard to clinical outcomes, a comparison was
made between clinical outcomes after 29 studies in which both
DI and PCRN exceeded 1.15 (well dialyzed and good protein
intake) and those after 38 studies in which both DI and PCRN
were less than 0.85 (poorly dialyzed and poor protein intake).
Even between these two extreme groups there were no signif-
icant differences in clinical outcomes (Table 3).
A further analysis examining data only from 15 patients who
had five or more studies also showed no correlation of DI,
KT/V and PCRN with subsequent clinical outcomes.
Finally, in the patient based analysis, average values for DI,
KT/V and PCRN over the first 24 months of CAPD in the 51
patients having two or more studies showed no correlation with
clinical outcomes during the first 30 months of CAPD.
Discussion
This study suggests that neither the DI nor KT/V, nor the
PCRN are predictive of clinical outcomes in CAPD patients.
These urea kinetic indices do predict serum levels of urea,
creatinine, potassium, bicarbonate and phosphate but they do
not predict more important clinical outcomes such as mortality,
technique failure, hospitalization and other subjective and
objective indices of morbidity. Thus, they appear not to be good
measures of adequacy of dialysis in CAPD patients.
These findings, which contrast with those from the National
Cooperative Dialysis Study in hemodialysis patients, are per-
haps less surprising when one considers the marked differences
between the two dialytic modes. Firstly, CAPD is well known
to have superior middle molecule clearance [8] and, while
substances in this molecular weight range have not conclusively
been shown to mediate the uremic syndrome, a role is strongly
suspected [9]. Secondly, CAPD is associated with steady levels
(76) (49) (32) (23) (16) (13) (7)
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of urea, creatinine and other uremic solutes in contrast to the
peaks and troughs of hemodialysis, and it has been hypothe-
sized that this may be less toxic to the patient [31. The same
could be argued with regard to the more stable hydration status
of the CAPD patient.
Also, there is evidence that residual renal function persists
longer in CAPD patients [10, 111, and this may more than
compensate for the technique's inferior urea kinetic perfor-
mance. Finally, it may be that morbidity and mortality in CAPD
are determined more by access related events such as peritoni-
tis and by the severity of any associated cardiovascular disease
than by the quantity of dialysis delivered [12].
Our study is the largest to date to address the application of
urea kinetics to CAPD. It could be argued that the numbers of
patients and observations are still not large enough to exclude a
beta error. However, the absence of even a trend towards
significant correlations with clinical outcomes reassures us that
this is unlikely.
It also might be suggested that our analysis missed a predic-
tive effect because the spread of values for DI (or KT/V) was
not wide enough. Thus, in the NCDS two of the four patient
groups were prospectively treated with a dose of hemodialysis
that would be considered very inadequate by modern standards
and this may explain why differences in clinical end points were
detected. In our study no randomization occurred and the dose
of CAPD was not prospectively determined and indeed, was
altered by patients' physicians on the basis of clinical criteria.
Such a study design makes it more difficult to detect significant
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Table 3. Comparison between
high DI and PCRN (both>
(both
clinical outcomes after studies with
1.15) and with low DI and PCRN
< 0.85)
High DI Low Dl
and PCRN and PCRN
Numbers 29 38
No. of deaths 2 2
No. of technique 2 5
failures
Hospital daysa 8.8 10.7
Peritonitis ratea 0.45 0.43
No. of transfusionsa 1.38 0.86
Fatigue index 0.92 1.18
Pruritus index 0.58 0.59
Insomnia index 0.67 0.65
Nerve conduction 39.5 39.8
rn/Sec
All differences were not significant at P < 0.05.
a All expressed per 6 month period.
differences in outcome. However, we would argue that the dose
of dialysis measured by KT/V differed by a factor of two
between the lowest 10% and the highest 10% of our patient
studies and that in 25% of all studies KT/V was less than 0.54.
This suggests both a wide spread of dialysis dosage and a
substantial amount of "underdialysis" by the yardstick of urea
kinetics. In spite of this, our analysis does not show even a
trend towards correlation with clinical outcomes; even in the
comparison between the best dialyzed, highest protein intake
group and the worst dialyzed, lowest protein intake group no
such differences were detected.
In theory, there is a dose of CAPD, as measured by urea
kinetics, below which an excess of morbidity and mortality will
occur, but this may be well below the range of doses delivered
in practice.
Another possible objection to our study is the high drop out
rate with only one quarter of the patients completing three to
four years of follow-up. We would argue that, while this is a
drawback, it is very typical of CAPD. The NIH funded National
CAPD Registry reports one and three year mortality rates of 17
and 42% and one and three year technique failure (excluding
death) rates of 20 and 44%. In the same registry, the transplant
rate at three years is 26% and the cumulative probability of
having discontinued CAPD for any reason by three years is 76%
[13]. In this context our death rate (17%), technical failure
(excluding death) rate (18%) and transplant rate (28%) over a
three to four year follow-up period are not excessive, and we
believe that high drop out rates are inevitable in long-term
studies of representative groups of CAPD patients.
A number of other points are apparent from our analysis. It is
important in any application of urea kinetics to CAPD to
remeasure indices frequently because DI, KT/V and PCRN all
tend to decrease with time on CAPD. This decline in KT/V and
DI was mainly related to residual renal function which de-
creased steadily until it was negligible by 30 months. It was, to
a lesser extent, related to decreasing ultrafiltration capacity
consequent upon increases in membrane permeability, as has
been previously reported [14], and also to the increase in body
weight which occurs with time in many patients.
A consequence of all this is that, after 12 months on CAPD,
few patients achieve the desired DI value of 1.0 with conven-
tional CAPD regimes. Similarly, by hemodialysis standards,
KT/V values which average 0.78 at the start of CAPD and
which decline to a mean of 0.62 after two years would seem
inadequate. Despite this appearance, confirmed in other studies
[3, 11], morbidity does not seem excessive in CAPD relative to
hemodialysis [4—6]. This paradox concerning adequacy of dial-
ysis in CAPD has been commented on by other authors [3, 11],
and could be interpreted as another reason to be skeptical about
the extrapolation of urea kinetic guidelines to this form of
dialysis.
We also demonstrated a close positive correlation between
DI and KT/V, on the one hand, and PCRN, on the other.
Similar degrees of correlation have recently been noted in two
smaller studies involving both hemodialysis and CAPD patients
[11, 15] and suggest that the dialytic dose, as measured by urea
kinetics, is an important determinant of a patient's protein
intake. This may represent a homeostatic mechanism through
which the body copes with and limits uremia by suppressing
appetite and so, protein intake. It also helps explain the decline
in protein intake with time on CAPD noted, both in this study
and previously [16].
The discrepancy between actual and recommended protein
intake is striking in this study and has been commented on
before [7, 11]. Intake was below the theoretically required level
for neutral nitrogen balance at the time of starting CAPD and
declined even further thereafter. In spite of this, many patients
appeared to do well and no correlation between low PCRN and
poor outcome was seen. The overall issue of optimal protein
intake in this population remains controversial.
In view of our findings, we believe that the unqualified
application of the urea kinetic model to CAPD is unjustified. In
particular, we do not believe that it is appropriate to prescribe
extra volumes of dialysate or greater frequencies of exchanges
solely in order to achieve an adequate DI, often at the expense
of the patient's quality of life. Rather, we would suggest
continuing evaluation of patients' signs and symptoms to judge
if dialysis is adequate. Similarly, unattainably high protein
intakes should not be prescribed as an end in themselves
without better evidence of their benefit.
We would, however, caution strongly against using this study
as a justification for not giving careful attention to the amount of
dialysis and nutrition prescribed for CAPD patients. Rather, we
would argue that urea kinetics may not provide the most
appropriate scale for measuring these parameters. In the future,
efforts in this important area of investigation should be concen-
trated on finding better models for predicting outcome. In
particular, attention might be given to higher molecular weight
substances or to indices of peritoneal permeability and trans-
port as well as to measurements of patient nutrition other than
the PCRN.
Reprint requests to Dr. Peter G. Blake, Department of Nephrology,
University of Alberta Hospital, Edmonton, Alberta T6G 2B7. Canada.
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